Animal Pharm is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Potent probiotic launched in Japan

Kyoritsu Seiyaku has launched MitoMax SUPER, a potent probiotic supplement containing Pediococcus acidilactici, a plant-derived Lactobacillus, for dogs and cats in Japan. The company, based in Tokyo, says that the probiotic will be the first one to be applied to companion animals in Japanese market. It claims that the product is completely different from existing Lactobacillus. P acidilactici can be preserved at room temperature for more than two years, and it is resistant to oxystress. Researchers confirmed that the probiotic was alive even after a one-week incubation period at 65 degrees Celsius. Ordinary Lactobacillus and Bifidobacterium cannot survive under such conditions. MitoMax SUPER can be delivered live to the intestine, as P acidilactici can survive under significant low pH conditions found in gastric acid. The product is manufactured by US-based Imagilin Technology, and is imported by Healthvision.

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AP007280

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel